Discovery and expression of a Pseudomonas sp. esterase as a novel biocatalyst for the efficient biosynthesis of a chiral intermediate of pregabalin

Fangxin Xu,Shaoyun Chen,Gang Xu,Jianping Wu,Lirong Yang
DOI: https://doi.org/10.1007/s12257-015-0069-1
IF: 3.386
2015-01-01
Biotechnology and Bioprocess Engineering
Abstract:The enantioselective biocatalytic hydrolysis of rac -2-carboxyethyl-3-cyano-5-methylhexanoic acid ethyl ester ( rac -cyanodiester, rac -CNDE) to obtain a key ( S )-intermediate is crucial for the synthesis of Pregabalin. The gene estZF172 from Pseudomonas CGMCC No. 4184, which encoded a novel esterase EstZF172 with excellent stereoselective catalysis capacity of ( R )-CNDE ( E = 95), was obtained from genomic library construction through activity screening. EstZF172 was identified to be a new member of the bacterial esterase/lipase Family VIII by sequence alignment, phylogenetic tree analysis and homology model analysis, with preference toward shortchain p -nitrophenyl esters. The esterase was functionally expressed in E. coli BL21(DE3), exhibiting a 120-fold improvement in catalytic activity (4027.5 U/L) over the wild strain (33.43 U/L) toward CNDE. For the chiral hydrolysis of rac -CNDE catalyzed by recombinant cells, the optimum operating temperature and pH were determined to be 35°C and 8.5, respectively, based on the biochemical characterization of the purified EstZF172. Finally, the yield and ee of ( S )-CNDE reached 47.7% and > 99.5% after reaction for 7 h with a substrate loading of 127.5 g/L (500 mM). The results suggested that EstZF172 is a potential biocatalyst for the synthesis of an important chiral intermediate of Pregabalin.
What problem does this paper attempt to address?